PRT811, a protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor, has exhibited clinical activity and an acceptable safety profile in patients with IDH-positive recurrent, high-grade glioma and splicing mutation (SPLC)-positive uveal melanoma treated in the dose-expansion stage of a phase 1 study (NCT04089449), consistent with findings from the dose-escalation stage of the trial.
Clinical Trials
KEYNOTE-716: Primary melanoma, not lymph nodes, should ‘drive therapeutic decision-making’
Three-year results show durable distant metastasis-free survival and RFS benefits with adjuvant pembrolizumab.
Fianlimab/Cemiplimab Demonstrates Early Clinical Activity and Safety in Advanced Melanoma
The LAG-3 inhibitor fianlimab plus cemiplimab (Libtayo) produced high and consistent tumor responses and a comparable toxicity profile to that of anti–PD-L1 monotherapies in patients with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study (NCT03005782) presented at the 2023 ASCO Annual Meeting.
Expert: KEYNOTE-716 Could be a “Game-Changer" for Patients with Stage 2 Melanoma At High Risk of Recurrence
Until this study, adjuvant immunotherapy was standard of care for stage 3B melanoma but not stage 2, which has relatively similar survival rates and risk of recurrence.